Introductory Paragraph {#S1}
======================

Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSG) and 12 thalamic gliomas. We also performed targeted mutational analysis of an additional 24 such tumors, and genome-wide methylation profiling of 45 gliomas. This study led to the discovery of tumor-specific mutations in *PPM1D,* encoding Wild type p53-Induced Protein Phosphatase 1D (Wip1), in 37.5% of the BSGs that harbored hallmark *H3F3A* K27M mutations. *PPM1D* mutations were mutually exclusive with *TP53* mutations in BSG and attenuated p53 activation in vitro. The *PPM1D* mutations were truncating alterations in exon 6 that enhanced the ability for PPM1D to suppress the activation of DNA damage response checkpoint protein Chk2. These results define *PPM1D* as a frequent target of somatic mutation and as a potential therapeutic target in brainstem gliomas.

We explored the genetic landscape of gliomas arising in well-defined locations throughout the brainstem and thalamus, from both pediatric and adult patients ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Whole exome sequencing was performed on 14 BSGs and 12 thalamic gliomas and matched normal blood (Online Methods). The coverage of bases in target regions with at least 10 reads is from 87% to 96% of all the samples ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). A total of 708 tumor-specific (somatic) mutations were discovered in these 26 samples (average 27 mutations per sample, [Supplementary Table 3](#SD2){ref-type="supplementary-material"} and [4](#SD2){ref-type="supplementary-material"}). 81 of 91 randomly selected mutated genes were validated by Sanger sequencing, reflecting an 89% sensitivity of our whole exome sequencing ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}).

The mutational landscape of the 14 BSG and 12 thalamic gliomas samples is displayed in [Fig. 1](#F1){ref-type="fig"}. This analysis confirmed that *TP53* and *H3F3A* were frequently mutated in both BSGs and thalamic gliomas (\>64% in both BSGs and thalamic gliomas)^[@R1]--[@R3]^. In addition, we confirmed the occurrence of *PDGFRA* alterations in these tumor types, with mutations identified in 1 BSG and 2 thalamic gliomas^[@R4]^. Also, an *FGFR1* N546K mutation that frequently occurs in pilocytic astrocytomas was identified in one of each of the BSG and thalamic gliomas, each of which also contained an inactivating *NF1* mutation^[@R5]^. Sanger sequencing for additional 8 samples shows two *FGFR1* V664L mutations in BSG. In total 4 out of 34 (12%) samples indicate *FGFR1* mutations are frequent in BSG and thalamic gliomas. Most importantly, this exome sequencing analysis led to the discovery of genes that had not previously been linked to the disease. Most notably, we found *PPM1D* mutations in 4 BSGs (29%) and *IDH1* mutations in 5 BSGs (36%). All these important recurrent mutations in these significantly-mutated genes were validated by Sanger sequencing.

To establish the prevalence of *PPM1D* recurrent mutations in BSG and to explore the relationship between *PPM1D* mutations and other alterations, we performed targeted sequencing on an additional 24 BSGs and thalamic gliomas. Sanger sequencing was performed on *PPM1D*, *IDH1,* *TP53*, and *H3F3A* for a total of 33 BSGs and 17 thalamic gliomas when including samples used for exomic sequencing ([Fig. 2](#F2){ref-type="fig"}). Among the extended series of 33 BSGs, 19 samples contained *TP53* mutations, 16 contained *H3F3A* mutations, 8 contained *IDH1* mutations, and 6 contained *PPM1D* mutations. In the extended series of 17 thalamic gliomas, we found 13 samples with *TP53* mutations and 11 samples with *H3F3A* mutations. All 27 *H3F3A* mutations in both BSG and thalamic gliomas were the hallmark K27M hotspot mutations associated with these midline tumor types^[@R2],[@R3]^. No *HIST1H3B* mutations, or *H3F3A* Arg34 mutations associated with supratentorial gliomas, were identified^[@R1]--[@R3]^. *PPM1D* mutations, as well as *IDH1* mutations, were completely absent in thalamic gliomas. Patients with *IDH1*-mutated tumors were significantly older than those with *IDH1*-wild type tumors (median age 43 vs. 24, *P* = 0.0056), but neither *H3F3A*, *TP53*, nor *PPM1D* mutational status delineated significant differences in patient age ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}).

Analysis of the extended series of tumors revealed that *PPM1D* mutations were only present in the subgroup of *H3F3A-*mutated BSGs (16/33 BSGs). Almost all *H3F3A*-mutated BSGs (15/16) contained either a *PPM1D* mutation or a *TP53* mutation in a completely mutually exclusive fashion (Fisher's exact test: *P* \< 10^−5^). Overall survival was not significantly different between patients with *TP53*-mutated and *PPM1D*-mutated brainstem gliomas ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}, [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). This mutual exclusivity and the similar clinical features of the patients suggest that *TP53* and *PPM1D* mutations may have equivalent oncogenic functions in BSG. An additional *PPM1D* mutation was identified in one of 57 cerebral gliomas, indicating that *PPM1D* mutations are uncommon events in gliomas arising outside of the brainstem.

All *PPM1D* mutations identified here were truncating mutations in exon 6. Six of the *PPM1D* mutations were nonsense mutations targeting Glu472, Leu484, Ser516, Glu525 (2 cases), and Glu540, while one was a frameshift mutation that disrupted Asn448 and resulted in a de novo stop codon ([Fig. 3a](#F3){ref-type="fig"}). Thus, all *PPM1D* mutations identified here truncate the C-terminal regulatory domain but leave the catalytic N-terminal PP2C phosphatase domain (residues 1-370) intact. *PPM1D* is a known oncogene that is amplified in breast and other cancers^[@R6]^. Also, remarkably similar truncating mutations in exon 6 of *PPM1D* have recently emerged as an unusual genetic risk factor for cancer after their discovery in germline tissues of rare (\<1%) breast, ovarian, and colorectal cancer patients^[@R7],[@R8]^. Additionally, both gain-of-function *PPM1D* genetic alternations and inactivating missense *PPM1D* mutations are found mutated at a low frequency in several types of cancer in available cancer data sets (<http://www.cbioportal.org>)^[@R9]^. The *PPM1D* mutations uncovered here establish truncating mutation in exon 6 of *PPM1D* as a frequent, tumor-specific (somatic) event in a type of cancer. To determine whether *PPM1D* mutation associates with different PPM1D protein expression patterns in tumors, we performed immunohistochemical analysis of PPM1D in a series of BSG tissues. No degradation or increased expression of PPM1D was identified in the *PPM1D*-mutated tumors compared to *PPM1D*-wild type tumors ([Fig. 3b](#F3){ref-type="fig"}).

Our targeted sequencing analysis also revealed a subgroup of BSGs with *IDH1* mutations (8/33, 24%). All *IDH1* mutations in BSGs were R132 hotspot mutations that are a hallmark of the supratentorial intermediate grade gliomas that occur in adults^[@R10]^. Among BSGs, *IDH1* mutations were mutually exclusive with *H3F3A* mutations (Fisher's exact test: *P* \< 10^−6^). Also, *IDH1* mutations occurred solely in adult cases (median age 43), which may explain why previous studies that focused solely on pediatric BSG patients did not identify *IDH1* alterations^[@R2],[@R3]^. Our series of BSGs may have had different characteristics from previous studies because we examined the exophytic portions of diffuse intrinsic gliomas that were accessible for surgical resection, while previous studies examined intrinsic tissue from diffuse intrinsic gliomas that may not have had associated exophytic portions^[@R2],[@R3]^.

We further determined whether BSG or thalamic gliomas exhibited epigenetic differences from supratentorial gliomas. To do so, methylation status of \>485k genomic loci was determined for BSG (n=17), thalamic gliomas (n=10), and supratentorial glioma (n=18) samples. These samples were then subjected to unsupervised hierarchical clustering, consensus clustering, and principal component analysis based on methylation β-values for the 2% most variant loci ([Fig. 4](#F4){ref-type="fig"}, [Supplementary Fig. 2 and 3](#SD1){ref-type="supplementary-material"}). Tumor location did not affect clustering of the samples based on these approaches. Rather, these clustering approaches identified three distinct groups corresponding almost perfectly to *IDH1* and *H3F3A* mutation status. *IDH1*-mutated tumors tend to be hypermethylated compared with non-mutated tumors regardless of whether they are located in the brainstem or supratentorium, whereas *H3F3A-*mutated tumors showed a hypomethylation phenotype ([Supplementary Fig. 4 and 5](#SD1){ref-type="supplementary-material"}), consistent with previous reports^[@R11]--[@R14]^. Notably, *PPM1D*-mutated and non-*PPM1D* mutated samples were intermingled within the *H3F3A* cluster. Gene Expression data of selected samples were analyzed by Gene Set Enrichment Analysis^[@R15],[@R16]^ ([Supplementary Table 8](#SD2){ref-type="supplementary-material"}). This analysis confirms the association between *IDH1* mutation, *H3F3A* mutation, and methylation status^[@R11]--[@R14]^, and indicates that location and *PPM1D* mutation status are not major contributors to tumor methylation status.

We next sought to examine the function of the *PPM1D* mutations revealed in our genome-wide mutational analysis of BSGs, especially in the context of radiation treatment, a key therapeutic modality for gliomas. PPM1D functions as a phosphatase that dephosphorylates and inactivates many DNA damage response mediators such as Chk2, p53, and H2AX^[@R17]--[@R19]^. Cancer-associated PPM1D truncation mutants attenuate p53 and H2AX activation following irradiation, possibly because PPM1D mutants are stabilized at the protein level due to loss of a C-terminal degradation signal^[@R8]^. To extend these findings, we assessed the impact of truncated PPM1D on p53, H2Ax, and Chk2 activation and examined the effect of repairing *PPM1D* mutation in a cell line with a native *PPM1D* mutation.

Glioma-derived PPM1D-E472X and E540X truncated mutants were introduced to HEK293T cells, which are *TP53* wild type. As controls, we also introduced wild type PPM1D, a phosphatase-dead PPM1D-D314A mutant^[@R20]^, or vector alone. Expression of the glioma-derived PPM1D mutants attenuated the increases in phospho-Thr68 Chk2, phospho-Ser15 p53, and γH2Ax following 10 Gy irradiation ([Fig. 5a](#F5){ref-type="fig"}). This effect was also achieved by expression of PPM1D-WT, but not by the phosphatase-dead PPM1D-D314A mutant. These results demonstrate that cancer-associated PPM1D truncation mutants retain phosphatase activity toward Chk2 and confirm that they retain phosphatase activity against p53 and H2Ax^[@R7],[@R8]^.

We next sought to dissect the contribution of *PPM1D* mutation to the biochemical and biological properties of *PPM1D*-mutated cancer cells. Since BSG-derived cell lines with *PPM1D* mutation have not been established, we focused on the HCT116 colorectal carcinoma cell line which contains a native *PPM1D*-L450X mutation^[@R8]^ at the same region of the mutations identified in BSGs. Using homologous recombination (Online Methods), we repaired the mutated *PPM1D* allele to create two isogenic *PPM1D* wild type cell lines ([Fig. 5b](#F5){ref-type="fig"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). After irradiation, the repaired *PPM1D* wild type cell lines had higher levels of Chk2 and of p53 phosphorylation than the *PPM1D*-mutant parental cell line ([Fig. 5c](#F5){ref-type="fig"}). γH2Ax was not increased by replacement of the mutant *PPM1D* allele, indicating that dynamic H2Ax phosphorylation may be regulated by other phosphatases in this cell line. Notably, cell growth and colony formation were decreased after repair of the mutant *PPM1D* allele ([Fig. 5d, 5e](#F5){ref-type="fig"}, and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}), indicating that mutant PPM1D drives growth of *PPM1D*-mutated cancer cells. These results demonstrate that mutant PPM1D contributes to cell growth, as well as to p53 and Chk2 dephosphorylation after radiation treatment.

In summary, our genomic and epigenomic analysis reveals *H3F3A-PPM1D* co-mutation and *IDH1-TP53* co-mutation as common genetic subtypes of BSGs, and confirms that *H3F3A-TP53* co-mutation commonly occurs in both BSGs and thalamic gliomas. We identified truncating mutations in exon 6 of *PPM1D* as frequent somatic events in a human tumor type, in the typical tumor-specific distribution expected for oncogenic mutations selected during tumor clonal evolution. The mutual exclusivity of *PPM1D* and *TP53* mutations together with the functional study results suggest that somatic mutations in either *PPM1D* or *TP53* are the genetic basis for dysfunction of the radiation-induced DNA damage response network in brainstem gliomas. Our data further show that these gain-of-function PPM1D mutants can suppress phosphorylation of Chk2 upon radiation-induced DNA damage stress and potentially abrogate cell cycle checkpoints.

This study adds another layer to the complex genetic role for *PPM1D* in cancer: in addition to the gain-of-function/truncating *PPM1D* mutations reported here in BSGs, germline mosaic gain-of-function/truncating *PPM1D* mutations have been linked to several other types of cancer^[@R7],[@R8]^, and still other rare tumors have been reported with loss-of-function/missense *PPM1D* mutations^[@R9]^. Assessment of *PPM1D* mutational status in future prospective trials will be necessary to determine whether *PPM1D* status is predictive of response to radiation or other therapies. Future studies that employ whole genome sequencing may identify additional alterations in these tumor types, and further studies on genetically engineered models of *PPM1D*-mutated gliomas, which have yet to be developed, will determine the precise mechanism by which *PPM1D* mutations confer a selective advantage in the glioma setting. Also, since small chemical inhibitors of PPM1D phosphatase activity are being explored^[@R21],[@R22]^, the finding of gain-of-function *PPM1D* mutations offers a potential therapeutic opportunity for a subgroup of patients with this challenging brain tumor type.

Online Methods {#S2}
==============

Patients {#S3}
--------

Brain tumor samples and peripheral blood of patients were collected from Beijing Tiantan Hospital, China from 2010 to 2012 with informed consent reviewed by Institutional Review Board. Total 107 samples were used in this analysis, 50 BSGs and thalamic gliomas and 57 supratentorial gliomas. Among 50 samples (33 BSGs and 17 thalamic gliomas), 26 samples were used for whole exome sequencing for preliminary screening, and total 50 samples were validated by Sanger sequencing. Survival data were displayed using Kaplan-Meier analysis and the log-rank test was used to test for survival differences between groups.

Sequencing and Copy Number Alterations {#S4}
--------------------------------------

Whole exome sequencing and copy number analyses were performed by Personal Genome Diagnostics, Inc., Baltimore, MD, Beijing Pangenomics Technology, Co. Ltd, and Softgenetics. A targeted approach, using Sanger sequencing, was performed to screen for additional mutations in a larger series of samples for a subset of the genes identified. Copy number amplifications were confirmed in targeted genes of *PPM1D* and *PDGFRA* by qPCR analysis. Randomly selected mutations were also validated by Sanger Sequencing to evaluate the sensitivity of whole exome sequencing. Sequencing primers were selected as previously reported^[@R25]^. PolyPhen-2 was applied to predict the functional effects of missense mutations^[@R26]^.

DNA Methylation {#S5}
---------------

Illumina HumanMethylation450 BeadChip was used for genome-wide methylation profiling of 18 BSG, 10 thalamic gliomas samples, and 20 supratentorial tumors including one duplicate sample for internal control and one cell line. GenomeStudio Methylation Module was used for data processing and quality check. The internal control showed almost perfect correlation with its duplicate (r=0.9978, *P* \< 10^−16^). One BSG sample was excluded for obviously considered as an outlier from other samples. Consensus clustering by GenePattern and hierarchical clustering by R package pheatmap were performed for evaluation of subgroups^[@R27]--[@R30]^.

Gene Expression Profiling {#S6}
-------------------------

Affymetrix Human Genome U133 Plus 2.0 Array was used for evaluation of gene profiling of samples (n=21) at Shanghai Biotechnology Corporation, China. Robust Multichip Average (RMA) method by R was used for data processing and normalization^[@R31]^. For gene expression subgroups classification, additional GBM samples (n=116) were obtained from the TCGA websites as training dataset. Classification to Nearest Centroids (ClaNC) was used for predicting the subtypes of our tumor samples^[@R32]^. Gene Set Enrichment Analysis was used to analyze the possible affected pathways^[@R15],[@R16]^.

Plasmid construction {#S7}
--------------------

The plasmids contain full-length wildtype PPM1D cDNA (pCMV-Neo-Bam-PPM1D) and D314A mutated PPM1D (pCMV-Neo-Bam-PPM1D D314A) with C-terminal Flag tags were obtained from Addgene (plasmids 28105 and 28106)^[@R20]^. To generate the truncating mutations (PPM1D472 and PPM1D540), the primers were used along with the QuikChange II Site Directed Mutagenesis Kit (Agilent, 200521)([Supplementary Table 9](#SD1){ref-type="supplementary-material"}).

Gene targeting of PPM1D mutant allele in HCT116 cells {#S8}
-----------------------------------------------------

The strategy for gene targeting in human cells has been described previously^[@R12]^. Briefly, targeting recombinant adenovirus associated virus (rAAV) construct was designed to replace the PPM1D L450X mutant allele with WT PPM1D allele. Homologous arms surrounding the insertion site were PCR-amplified from human blood DNA using platinum taq HIFI polymerase (Invitrogen, 11304). The infectious rAAV stock was prepared and applied to the HCT116 cell line as previously described^[@R33]^. DNA of G418-resistant clones were extracted and screened by PCR and PPM1D status of the resulting positive clones was validated by direct Sanger sequencing. Two validated clones of which the PPM1D L450X mutation was successfully repaired were further treated with Cre recombinase adenovirus (Vector Biolabs, 1045) to remove the drug-resistance cassette.

Cell culture, transfection and irradiation {#S9}
------------------------------------------

HEK293T cells (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, 11965) with 10% fetal bovine serum (FBS) (Gibco); HCT116 parental and isogenic cells were grown in McCoy5A medium (Invitrogen, 16600) with 10% FBS; for transfection experiments, 293T cells were plated in 6-well plates (50%--70% confluence) and were transfected with 2 µg of plasmid using Lipofectamine 2000 (Invitrogen, 11668027). After 24 h transfection, the cells were exposed to 10 Gy gamma irradiation (X-ray) and were harvested at 1 and 5 hours post-irradiation. The HCT116 parental and isogenic cell lines were exposed to gamma irradiation with the same settings. The Cell Counting Kit-8 (Dojindo, CK04-13) was used to determine relative cell counts according to the manufacturer's protocol.

Colony formation assay {#S10}
----------------------

HCT116 parental and its derived isogeneic cells were seeded in quadruplicate. After 12 hours incubation, cells were exposed to gamma irradiation 0 Gy (500 cells per well on a 6-well plate), 2 Gy (500 cells), and 4 Gy (2000 cells) from an X-ray source. Cells were fixed with ice-cold methp.15anol and stained with 0.05% crystal violet solution after 8--10 days incubation. Colonies were counted and the p value was calculated by Wilcoxon rank sum test.

Western Blot and Immunohistochemistry {#S11}
-------------------------------------

Protein expression and modification were determined by Western blotting using standard means. The cells were washed with ice cold 1 × PBS twice followed by treatment with RIPA lysis buffer (Santacruz, sc-364162) supplemented with protease inhibitor cocktail (Santacruz, sc-29130) and sodium orthovanadate. After sonication and centrifugation, the protein concentrations of supernatants were quantified by bicinchoninic acid (BCA) assay. A total of 20 µg of proteins were denatured at 70°C for 10 min with NuPAGE® LDS Sample buffer (Life Technology, NP0007) and resolved by electrophoresis. The proteins were transferred to a nitrocellulose membrane. Membranes were blocked by 5% BSA or 5% fat free milk according to the antibodies datasheet. After blocking, membranes were incubated with a primary antibody: mouse anti-PPM1D (Santacruz, sc-376257); rabbit anti-GAPDH (Santa Cruz, SC-25778); rabbit anti-P53 (Cell Signaling, 9282); rabbit anti-phospho-P15 Ser15 (Cell Signaling, 9284); rabbit anti-CHK2 (Santa Cruz, SC-9064); rabbit anti-CHK2 T68 (Cell Signaling, 2661); rabbit anti γ-H2AX (Cell Signaling, 9718) and rabbit anti-H2AX (Cell Signaling, 7631) at 4°C overnight at dilutions specified by the manufacturers. The membranes were washed three times with 0.5% Tween-20 (TBST) before incubated with secondary antibodies (ECL anti-rabbit IgG or ECL anti-mouse IgG, GE Life Science) and detected by ChemiDoc™ MP System (BIO-RAD). Immunohistochemisty was performed on 5-µm formalin-fixed, paraffin-embedded tissue sections using a rabbit polyclonal antibody raised against the N-terminus of PPM1D (Abcam, ab60243) at a 1:100 dilution according to the manufacturer's instructions.
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![Exome sequencing results for BSG and thalamic gliomas. (a) The frequency of mutations per case. A: Astrocytoma; O: Oligodendroglioma; OA: Oligoastrocytoma; GBM: Glioblastoma (b) The overview for mutation status of genes mutated in at least 2 cases. No deletions were detected in these genes. (c) The frequency of mutation per gene.](nihms593687f1){#F1}

![Mutation status of *TP53*, *PPM1D*, *H3F3A*, *IDH1* in the extended series. Mutational status as determined by Sanger sequencing is shown for BSGs (n=33) and thalamic gliomas (n=17).](nihms593687f2){#F2}

![Landscape of PPM1D mutations and IHC staining of PPM1D in tumor samples. (a) All mutations occurred in the C-terminal portion of PPM1D, leaving the phosphatase domain untouched. All mutations were identified in BSGs, except E472X which was identified in a cerebral glioma. (b) Tumors with or without PPM1D mutations were selected for IHC staining with an N-terminal anti-PPM1D antibody. PPM1D-WT (case ID); PPM1D-mutant (case ID, mutation type). Scale bar, 100 µm.](nihms593687f3){#F3}

![Heatmap of variant methylation probes in 45 glioma samples, with genetic information. Forty-five glioma samples (columns) and top 2% variant probes (rows) are arranged by unsupervised average-linkage hierarchical clustering. *IDH1* mutated, *H3F3A* (K27)-mutated, and WT samples clustered separately by unsupervised average-linkage hierarchical clustering. Within the *IDH1* mutated subcluster, two hemizygous *IDH1* mutation samples described previously^[@R23]^ were included (marked as light green in the status of *IDH1*), which showed distinct methylation patterns compared with other *IDH1*-mutated samples. Gene expression-based classification into proneural, neural, classical, and mesenchymal subtypes by TCGA classification^[@R24]^ is shown for samples for which material was available for gene expression analysis.](nihms593687f4){#F4}

![The effect of cancer-derived truncated PPM1D on Chk2, p53, and H2AX activation and cell growth. (a) HEK293T cells transfected with full length wild type, E472X truncated PPM1D, E540X truncated PPM1D, and D314A PPM1D were exposed to ionizing radiation (IR, 10Gy). Cells were collected before IR and 1 h and 5 h after IR. Whole cell lysates were analyzed for Chk2 Thr68 phosphorylation, p53 Ser15 phosphorylation, γ-H2AX, and GAPDH. Western blot against PPM1D showed successful transfection. (b) Gene targeting to repair a native PPM1D mutation. HCT116 cells contain a heterozygous frameshift deletion that results in a truncated PPM1D mutant (L450X). Homologous recombination was used to replace the mutated PPM1D allele with wild type PPM1D in two HCT116 sublines. Western blot demonstrates expression of full length and truncated PPM1D in the parental cell line, but only full length PPM1D expression in the two repaired cell lines. PPM1D-F: Full length PPM1D. PPM1D-T: Truncated PPM1D. (c) HCT116 parental (PPM1D mutant) and two isogenic repaired lines (PPM1D wild type) were exposed to ionizing radiation (IR, 10 Gy). Cells were collected before IR and 1 h and 5 h after IR. Whole cell lysates were analyzed for Chk2 Thr68 phosphorylation, p53 Ser15 phosphorylation, γ-H2AX, and GAPDH. (d) Proliferation assay for HCT116 parental cell line (PPM1D mutant) and isogenic repaired lines (PPM1D wild type). 1000 cells were seeded in each well (triplicates) of 96-well plates on day 0. Relative cell number was determined each day after seeding. Error bars represent mean ± SEM. (e) Colony formation by PPM1D-mutant HCT116 parental cell line and isogenic wild type PPM1D lines. Colony formation was assessed in the absence of IR, and under 2 Gy, or 4 Gy IR. *P* \< 0.05 (\*) between parental cells and isogenic repaired line 1 or 2 under 0 Gy, 2 Gy, and 4 Gy IR. n=4, error bars represent mean ± SEM.](nihms593687f5){#F5}
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